Clinical Properties of Current Food and Drug Administration–Approved Molecular Tracers Detecting Protein Folding or Misfolding
| Property | Description |
|---|---|
| Indication | |
| 18F-florbetapir | Imaging β-amyloid plaques in suspected AD patients |
| 18F-florbetaben | Imaging β-amyloid plaques in suspected AD patients |
| 18F-flutemetamol | Imaging β-amyloid plaques in suspected AD patients |
| 18F-flortaucipir | Imaging aggregated tau neurofibrillary tangles in suspected AD patients |
| Administered dose for adults | |
| 18F-florbetapir | 370 MBq (10 mCi) |
| 18F-florbetaben | 296 MBq (8 mCi) |
| 18F-flutemetamol | 185 MBq (5 mCi) |
| 18F-flortaucipir | 370 MBq (10 mCi) |
| Injection route | Intravenous |
| Injection-to-imaging time | |
| 18F-florbetapir | 30–50 min |
| 18F-florbetaben | 45–130 min |
| 18F-flutemetamol | 80–100 min |
| 18F-flortaucipir | 80–100 min |
| Normal biodistribution | |
| 18F-florbetapir | Inner white matter, from which blood clearance is slower |
| 18F-florbetaben | Inner white matter, from which blood clearance is slower |
| 18F-flutemetamol | Inner white matter, from which blood clearance is slower |
| 18F-flortaucipir | Some normal retention in choroid plexus, striatum, and brain stem nuclei |
AD = Alzheimer disease.